Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Biochemical Pharmacology
|
February 5, 2003
Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo
Michail V Sitkovsky
Cancer Discovery
|
January 11, 2020
Lessons from the A2A Adenosine Receptor Antagonist-Enabled Tumor Regression and Survival in Patients with Treatment-Refractory Renal Cell Cancer
Michail V Sitkovsky
Current Opinion in Pharmacology
|
August 31, 2020
Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy
Michail V Sitkovsky
Trends in Immunology
|
February 10, 2009
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response
Michail V Sitkovsky
Blood
|
August 30, 2003
Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo
Gregorio Gomez, Michail V Sitkovsky
Trends in Immunology
|
June 1, 2005
The 'danger' sensors that STOP the immune response: the A2 adenosine receptors?
Michail V Sitkovsky, Akio Ohta
The Journal of Biological Chemistry
|
October 8, 2010
Adenosine A2A receptor is involved in cell surface expression of A2B receptor
Kengo Moriyama, Michail V Sitkovsky
The International Journal of Biochemistry & Cell Biology
|
February 5, 2003
Targeting G protein-coupled A2a adenosine receptors to engineer inflammation in vivo
Gregorio Gomez, Michail V Sitkovsky
The Journal of Clinical Investigation
|
September 2, 2020
Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy
Stephen M Hatfield, Michail V Sitkovsky
Current Pharmaceutical Design
|
July 23, 2003
HIF-1 alpha deficiency perturbs T and B cell functions
Hidefumi Kojima, Michail V Sitkovsky, Marilia Cascalho
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Biochemical Pharmacology
|
February 5, 2003
Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo
Michail V Sitkovsky
Cancer Discovery
|
January 11, 2020
Lessons from the A2A Adenosine Receptor Antagonist-Enabled Tumor Regression and Survival in Patients with Treatment-Refractory Renal Cell Cancer
Michail V Sitkovsky
Current Opinion in Pharmacology
|
August 31, 2020
Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy
Michail V Sitkovsky
Trends in Immunology
|
February 10, 2009
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response
Michail V Sitkovsky
Blood
|
August 30, 2003
Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo
Gregorio Gomez, Michail V Sitkovsky
Trends in Immunology
|
June 1, 2005
The 'danger' sensors that STOP the immune response: the A2 adenosine receptors?
Michail V Sitkovsky, Akio Ohta
The Journal of Biological Chemistry
|
October 8, 2010
Adenosine A2A receptor is involved in cell surface expression of A2B receptor
Kengo Moriyama, Michail V Sitkovsky
The International Journal of Biochemistry & Cell Biology
|
February 5, 2003
Targeting G protein-coupled A2a adenosine receptors to engineer inflammation in vivo
Gregorio Gomez, Michail V Sitkovsky
The Journal of Clinical Investigation
|
September 2, 2020
Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy
Stephen M Hatfield, Michail V Sitkovsky
Current Pharmaceutical Design
|
July 23, 2003
HIF-1 alpha deficiency perturbs T and B cell functions
Hidefumi Kojima, Michail V Sitkovsky, Marilia Cascalho
Page
of 4